Rivervest https://validator.w3.org/feed/docs/rss2.html ANNOUNCEMENT / Teleflex to Acquire Standard Bariatrics Flex Vascular, Inc. Portfolio Company Bluejay Therapeutics to be Acquired by Mirum Pharmaceuticals Portfolio News John McKearn, Ph.D. RIVERVEST NEWS: February Newsletter Nafiseh Masoumi Team JPM 2026 Recap: Signals Are Getting Clearer InterVene, Inc. Case Studies Lumena Pharmaceuticals, Inc. Mirum Pharmaceuticals Mirum Pharmaceuticals, Inc. Bluejay Therapeutics RIVERVEST NEWS: June Newsletter Portfolio About Accessibility Statement MaxWell Biomedical Year in Review 2025 Biolinq Newsletter With $115 Million in Hand, Biotech Startup Eyes the Finish Line Could Excess Cortisol Be Driving Type 2 Diabetes Resistance? Newsletter Signup NEWS / RiverVest Mourns Passing of Ronald T. Borchardt, PhD Peter Tontonoz, M.D., Ph.D. Newsletter Signup v1 The Sugar Fix: A New Approach to Treating a Rare Glycosylation Disorder RiverVest Venture Partners Welcomes Brandon Cohen as Analyst Brandon Cohen Jay W. Schmelter Alessandro Sette, Dr. Biol. Sci. Niall O’Donnell, Ph.D. Meet the Leader: Lyn Baranowski, CEO of Avalyn Pharma RiverVest Venture Partners Welcomes Nafise Masoumi as Senior Associate Managing Risks, Maximizing Investor Returns, by Tom Melzer The Orphan Drug Act of 1983 by Niall O’Donnell Niall O’Donnell Discusses State of Biotech VC with St. Louis Business Journal Mitochondrial Challenges: Innovations in Research and Patient-Centered Care Pascal Krotee Wins Life Science Catalyst Award RiverVest Venture Partners Promotes Karen Spilizewski and Isaac Zike to Managing Director and Pascal Krotee to Principal Global Clinical Trial Investigates Novel Heart Failure Treatment News Portfolio Company Spotlight: Engrail Therapeutics (Anxiety Disorders) Niall O’Donnell, Ph.D. Honored by UC San Diego’s Rady School of Management’s Sullivan Center for Entrepreneurship RiverVest Venture Partners Promotes Andrew Kleiboeker and Jeff Seitz Diabetes Treatment: A Story of Complicated Progress and Great Potential Home